Amy and Simon Blog

The Natural and Healthy Lifestyle we Discovered Along the Way…

Be careful where you put your research dollars August 25, 2009

Filed under: The E.C.H.O. Foundation — dottys @ 10:00 pm
Tags: ,
God I hate doing this, but just another thing I have been yelling about since Autism Speaks was first established. All non profits are not created equal and some are just plain money makers. I worked for an 501c3 for 6 years. I saw the ins and outs of what a non profit can and can not do and it really made me take a second look at charitable organizations. Now I do not donate a dime unless I know for sure where the money is going. I check out endorsers, research, philosophies, etc.and yes even payroll. A 501c3 is a public non profit, which means the public is entitled to know where their money is going. Here is an example of what Autism Speaks is spending your money on.
BTW if you want to support good, honest independent autism research please check out Dr. Wakefield’s org  http://www.thoughtfulhouse.org/.
Let’s Speak the Truth!
Dotty Scalco
In response to my prior post on the captioned subject I received the following.  While I can’t verify every aspect, I am not surprised and find it outrageous.  Given that that Autism Speaks is a publicly supported charity I believe an explanation is owed to its supporters.
===============”One of the most eye-catching revelations in examining the Form 990 (Return of Organization Exempt from Income Tax) of Autism Speaks is the compensation paid to its Chief Science Officer, Geraldine Dawson.

According to Schedule J, Part II of the Form 990, Ms. Dawson received base compensation of $373,360 during 2008. In addition, she received what is described as “other compensation” of $270,904 during 2008. Also included was “deferred compensation” of $3,750 and “nontaxable benefits” of $21,737. In total, she received total compensation package during 2008 of $669,751!

The “other compensation” is described by Autism Speaks in their Form 990 as a “one time relocation payment.” What is very interesting is that prior to Ms. Dawson’s employment with Autism Speaks, she was Professor of Psychology and Psychiatry at the University of [State of] Washington (UW) and a founding director of the UW Autism Center. The relocation allowance of $270,904 paid to Ms. Dawson was for her move from the State of Washington to the State of North Carolina. To date, Autism Speaks does not have an office in North Carolina. But what is particularly interesting is that Ms. Dawson’s family resides in North Carolina and has resided there for some time. Apparently this was a way for Ms. Dawson to move closer to her family on somebody else’s dime and Autism Speaks was more than happy to accommodate her. Upon moving, she became a Research Professor of Psychiatry at the University of North Carolina at Chapel Hill. Whether the University of North Carolina paid her a relocation allowance is not known. Was her move to North Carolina really for the benefit of her employer?

Autism Speaks has three main offices – one in New York City (their national headquarters), one in Princeton, New Jersey (a satellite office) and one in Los Angeles, California, which headquarters their science operations. Presumably Ms. Dawson, as Chief Science Officer of Autism Speaks would be headquartered in the Los Angeles office. This is not the case. That said, proximity to the Los Angeles office is closer from Washington State than North Carolina.

The compensation package paid by Autism Speaks to Ms. Dawson borders on the criminal. Autism Speaks as a tax exempt 501(c)(3) charity essentially reports not to stockholders but to the general public at large. They have a solemn public responsibility to spend the funds they raise from the general public in a responsible and wise manner. The organization has acted grossly irresponsible in this case.”

=================================================

On Mon, Aug 10, 2009 at 5:52 PM, Marty <martyx44@verizon.net> wrote:

Autism Speaks 2008 Federal Form 990 was just forwarded to my attention.  The entire filing can be found at http://www.autismspeaks.org/docs/Autism_Speaks_Form_990_2008.pdf

Of particular note is that Geraldine Dawson earned from AS during 2008 the following:

Base compensation        $373,360

Other compensation       $270,904

Deferred comp               $ 3,750

Non-taxable benefits       $21,737

Total compensation       $669,751.

According to the 990, $269,721 of the compensation is a “one time relocation allowance.”  No further details provided.

Reasonable people can differ on the impact of this but given all the focus lately on compensation and considering the facts that Autism Speaks is a publicly supported charity, I think this speaks for itself.  I set forth the entire schedule J for this Non-for-profit and you can reach your own conclusion.

 

$1000 Per Day Fine And 30 Days In Jail For Refusing The Swine Flu Vaccine In MA August 24, 2009

Some people have asked me what will happen if I refuse the swine flu this fall.
Well seems Massachusetts is already setting up laws to answer that question. Don’t blink folks, it may soon be nationwide…… Dotty Scalco


$1000 Per Day Fine And 30 Days In Jail For Refusing The Swine Flu Vaccine In Massachusetts?

A new law just passed in Massachusetts imposes fines of up to $1000 per day and up to a 30 day jail sentence for not obeying authorities during a public health emergency. So if you are instructed to take the swine flu vaccine in Massachusetts and you refuse, you could be facing fines that will bankrupt you and a prison sentence on top of that.

The YouTube video below is of a news report about this disturbing new law. In particular, pay attention at the 1:40 mark when the anchor and reporter discuss the new penalties for not obeying the health authorities during an emergency…..

 

Health Freedom August 19, 2009

Filed under: The E.C.H.O. Foundation — dottys @ 7:39 pm
Tags:
For those of you that do not know Dr. Tedd Koren, he has been fighting for OUR health rights for many years.  Dr. Koren doesn’t just travel the world teaching parents and professionals, he has been highly active in the court systems as well.  To me, Dr. Koren is ” the guy”. The guy that made it all clear to me.
Dr. Koren was also the first person who recommended a homeopath to me. I had so much respect for the man, I listened and I am very thankful that I did.  If you can support any org. this month or year, let it be his and please look at the petition he has put together with some other great individuals. If anyone can make a difference it is Tedd.
Dr. Koren isn’t just my guy..he’s the man!!!…Dotty Scalco
***********************************************
It’s starting.  Here is our attack against the vaccine monolith.  This is just the beginning.I’d like to thank everyone who supports the Foundation for Health Choice.  Our attorney Jim Turner had a major part in this petition.  This is no mere petition, our goal has been to avoid doing what failed in the past and to go for weakest link in the government’s arguments.

We need to keep this going.  Go to www.foundationforhealthchoice.com and please donate.  Even if it’s just $25.00 a month, it’ll help a lot.

Here is the press release –

Three attorneys and several health freedom organizations have just filed a petition with the FDA to challenge the licensing of pan flu vaccines.

This approach bypasses the flaws of other legal action approaches (injunctions, etc.), and may actually work.

See Gary Null’s radio show today 1-3pm on this! (Wed Aug 19) Ralph Fucetola of Natural Solutions Foundation, Jim Turner of the D.C. firm Swankin-Turner, Alan Phillips of VaccineRights.com. Signatories include Gary Null, Tedd Koren, DC, and several others.

Citizen Petition: www.healthfreedomusa.org/?p=3314

******************************************************
E.C.H.O.
Educating on Children’s Health Options
www.TheEchoFoundation.com
ECHO the truth.
Be a voice for your child
 

Live Vaccine for Children Safety in Question August 18, 2009

Nice article but let’s just use a bit of common sense here….if you SPRAY a LIVE virus into the nasal cavity, do you think it will all go directly into the system or do you think it will drip all over the damn place and mist into the air. MORONS!!!…Dotty Scalco
http://www.i-sis.org.uk/LASIVCSQ.php

ISIS Press Release 17/08/09

Live Attenuated Swine Influenza Vaccine for Children Safety  in Question

The live attenuated swine flu vaccine intended for millions of children has dangerous side effects and is genetically unstable, risking generation of new pandemic strains should mass vaccinations go ahead.
Prof. Joe Cummins and Dr. Mae-Wan Ho

This report has been submitted to Sir Liam Donaldson, UK Chief Medical Officer, and to the US Food and Drug Administration Please circulate widely, with all the hyperlinks included, to your elected representatives, wherever you are

The swine flu vaccines being prepared for release to combat the current pandemic will be fast tracked without the usual clinical trials to ensure their safety. Five different companies were contracted to produce vaccines worldwide – Baxter International, GlaxoSmithKline, Novartis. Sanofi-Aventis and AstraZeneca – using a range of technologies from traditional chicken egg production to cell culture [1] ( Fast-tracked Swine Flu Vaccine under Fire , SiS 43).

Most of the vaccines will not contain live virus and will be delivered by injection. However AstraZeneca will produce a genetically engineered live attenuated vaccine through its global biologics unit, MedImmune, using cell culture or eggs [2]. The MedImmune vaccine will be used primarily for children, to be delivered as a nasal spray. The nasal spray vaccine against pandemic H1N1 influenza has been fast tracked for global distribution [3].

The live-attenuated vaccine appears more effective than the inactivated virus vaccine, but it resulted in significantly higher rates of severe adverse events. Furthermore, there is evidence that the live vaccine is highly genetically unstable in warm body cells and that has not been thoroughly evaluated in the children vaccinated .

Live attenuated versus inactivated influenza vaccine

MedImmune sponsored a safety and efficacy trial of the nasal spray live- attenuated, cold adapted (see below) influenza vaccine compared with inactivated vaccine on infants and young children 6 to 59 months of age [4]. . The study was conducted at 249 sites in 16 countries; US (49 percent of subjects), 12 countries in Europe and Middle East (45 percent), and 3 countries in Asia (6 percent).

A total of 7852 children completed the study. The results showed that there were 54.7 percent fewer cases of culture-confirmed influenza in the group that received live attenuated vaccine than in the group that received inactivated vaccine (153 cases, 3.9 percent vs 338 cases, 8.6 percent). For all culture-confirmed symptomatic influenza (both vaccine and non-vaccine strains), the overall attack rates were 5 percent in the group that received live attenuated vaccine and 10.0 percent in the group that received inactivated vaccine, indicating that neither vaccine was particularly good at preventing illness from non-vaccine strains. These results broadly confirm those of a comprehensive review carried out in 2006-2008, which could not provide safety analysis [5].

It is important to note that the MedImmune study explicitly excluded children with a history of hypersensitivity to any component of the live attenuated vaccine or the inactivated vaccine, known immunosuppressive condition , medically diagnosed or treated wheezing within 42 days before enrolment, a history of severe asthma , body temperature higher than 37.8 C within 3 days before enrolment and the use of aspirin or salicylate-containing products within 30 days before enrolment. The conditions italicized are precisely those considered especially at risk from swine flu and identified as ‘priority groups’ for receiving the vaccine by the UK government, which intends to vaccinate the entire UK population starting in October [6], and there is already evidence that the inactivated flu vaccine tripled the risk of severe events in children with asthma [7]. These findings are confirmed in the Medimmune study, which exposes the highly inadequate safety considerations in the UK government’s mass vaccination programme.

The results showed that among previously unvaccinated children, wheezing within 42 days after the administration of dose 1 was more common with live attenuated vaccine, primarily among children 6 to 11 months of age, which had 12 more episodes of severe wheezing (3.8 percent, compared with 2.1 percent, p=0.076). Furthermore, rates of hospitalization for any cause during the 180 days after vaccination were significantly higher among the recipients of live attenuated vaccine who were 6 to 11 months of age (6.1 percent compared with 2.6 percent, p = 0.002).

The authors stated [4, p. 694]:“Until additional data are available, the observations related to medically significant wheezing and rates of hospitalization will restrict the use of live attenuated vaccine in children younger than 1 year and in children 12 to 47 months of age who have a history of asthma or wheezing.”

With that proviso, perhaps, they concluded that an “evaluation of the risks and benefits indicates that live attenuated vaccine should be a highly effective, safe vaccine for children 12 to 59 months of age who do not have a history of asthma or wheezing

Immunizing school children finds favour with governments because it provides herd protection for the population and is considered more effective than immunizing elderly and high risk patients [8]. The MedImmune nasal live attenuated influenza vaccine for seasonal and pandemic influenza is called FluMist.

Producing live attenuated influenza vaccine

Influenza virus infection depends on two genes coding for haemagglutinin (HA) and neuraminidase (NA). HA and NA are on the surface of the virus, and are therefore targets for vaccination. Because classical reassortment methods (see [1]) for producing influenza vaccine are time-consuming and cumbersome, a new , more efficient and faster “reverse genetics” method was devised that assembles RNA virus from the genes on DNA plasmids. For vaccine production, eight plasmids -containing the HA and NA genes from pathogenic influenza strains plus six genes from a non pathogenic master strain – along with additional plasmids encoding proteins necessary for replication and transcription, are transfected into cell lines [9]. Virus can then be harvested from these cells for the production of inactivated or live attenuated vaccine. ` Live attenuated influenza vaccine (LAIV) was originally derived by cold adaptation of an influenza type A strain by serial passage at sequentially lower temperatures in chick kidney cells. During that process, multiple gene mutants were selected for cold adapted (ca), temperature sensitive (ts) and attenuated (att) phenotypes of master donor viruses (MDVs). The MDVs represent the live attenuated virus backbone that are updated for annual influenza or pandemic influenza HA and NA genes from disease strains The vaccine seed strain selected in the process is then used to produce quantities of live attenuated vaccine. No preservatives are added to the vaccine produced from the vaccine seed strain [10].

The Madin-Darby canine kidney (MDCK) cell line was chosen to produce quantities of live attenuated influenza vaccine (LAIV). The MDCK cell line was compared with the Vero cell line derived from kidney epithelial cells of the African green monkey and other cell lines derived from foetal lungs of humans or Rhesus monkey. Both MDCK and Vero cell lines supported high level production of LAIV for some strains of the virus while the other cell lines were less productive. However, only the MDCK cells produced quantities of all of the LAIV strains [11].

Problem with genetic instability of LAIV

LAIV replicates primarily in the ciliated epithelial cells of the nasopharyngeal mucosa to induce mucosal immune responses. LAIV viruses do not replicate well at the warmer temperatures found in the lower airways and lung. In the course of replication, all LAIV viral proteins would be presented to the immune system in their native conformation and the resultant immune responses mimic those of natural infection with influenza virus [10].

A potential problem was observed in studies of LAIV as it encounters restrictive temperature in the lung. The viral polymerase function is reduced and virus replication, assembly, and release become impaired [12]. The morphology of the temperature restricted virus was affected and the virus particles contained high levels of heat shock protein. Impairment of the viral replicase is a matter of concern because replicase may create new pandemic strains. Restrictive replication of LAIV at the restrictive temperature occurs in multiple steps in the virus replication cycle [13]. Shedding of LAIV is observed in individuals between 5 to 49 years of age up to 11 days after vaccination, and vaccinated individuals were advised to avoid contact with severely inmunosuppressed individuals for a week after vaccination [14].

Millions of children may soon be vaccinated with LAIV. But there is a large deficit in scientific studies on the molecular biology of LAIV exposed to restrictive temperature. The restricted viruses are genetically unstable and may result in gene alterations that serve to seed pandemic strains of influenza. This possibility must be thoroughly investigated before we expose millions more people to such live viruses.

References

  1. 1  Ho MW and Cummins J. Fast-tracked swine flu vaccine under fire ISIS Report 27/07/09 http://www.i-sis.org.uk/fastTrackSwineFluVaccineUnderFire.php ; also SiS 43 (in press).
  2. 2  MedImmune pandemic flu vaccine 2009 http://www.medimmune.com/pipeline/pipeline_phase1_detail.asp
  3. 3  MedImmune making significant progress in development of live attenuated nasal spray vaccine for novel influenza A (H1N1) 2009, http://www.medimmune.com/h1n1.asp
  4. 4  Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, Kemble G, Connor EM; CAIV-T Comparative efficacy study group. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007, 356(7), 685-96.
  5. 5  Jefferson T, Rivett A, Harnden A, DiPietrantoni C, and Demicheli V. Vaccines for preventing influenza in healthy children (Review). Cochrane Database Systematic Review 23 April 2009,
  6. http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004879/pdf_fs.html
  7. 7  “Swine flu latest from the NHS”, NHS choices, 13 August 2009, http://www.nhs.uk/news/2009/04April/Pages/Swineflulatest.aspx
  8. 8  Flu vaccination may triple risk for flu-related hospitalization in children with asthma, 25 May 2009, http://www.medscape.com/viewarticle/703235
  9. 9  Glezen WP Universal influenza vaccination and live attenuated influenza vaccination of children. Pediatr Infect Dis J 2008, 27(10 Suppl), S104-9.
  10. 10  WARF Improved reverse genetics method to produce influenza virus, 2009
  11. 11  http://www.warf.org/technologies.jsp?techfield=Pharmaceuticals&msnum=885&casecode=P04379US
  12. 12  Ambrose CS, Luke C, Coelingh K. Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza. Influenza Other Respi Viruses 2008, 2(6), 193-202.
  13. 13  Liu J, Shi X, Schwartz R, Kemble G. Use of MDCK cells for production of live attenuated influenza vaccine. Vaccine 2009 Jun 24. in press doi:10.1016/j.vaccine.2009.06.024
  14. 14  Chen Z, Aspelund A, Kemble G, Jin H.Molecular studies of temperature-sensitive replication of the cold-adapted B/Ann Arbor/1/66, the master donor virus for live attenuated influenza FluMist vaccines. Virology 2008, 380(2), 354-62.
  15. 15  Chan W, Zhou H, Kemble G, Jin H. The cold adapted and temperature sensitive influenza A/Ann Arbor/6/60 virus, the master donor virus for live attenuated influenza vaccines, has multiple defects in replication at the restrictive temperature. Virology 2008, 380(2), 304-11.
  16. 16  Block SL, Yogev R, Hayden FG, Ambrose CS, Zeng W, Walker RE. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age. Vaccine. 2008, 26(38), 4940-6.

E.C.H.O.
Educating on Children’s Health Options
www.TheEchoFoundation.com
ECHO the truth.
Be a voice for your child
 

Autism 1 in 100 August 11, 2009

Filed under: The E.C.H.O. Foundation — dottys @ 10:58 pm
Tags: ,
Just when i think I find peace, something has to knock me off kilter.
Wake up people. These little angels are coming here to wake us up. When will we say ENOUGH!!
My heart carries shame tonight.  Dotty Scalco
E.C.H.O.
Educating on Children’s Health Options
www.TheEchoFoundation.com
ECHO the truth.
Be a voice for your child
 

Journal of Toxicology

Severity of Autism Is Associated With Toxic Metal Body Burden and Red Blood Cell Glutathione Levels
Adams J et al
Journal of ToxicologyAbstract: This study investigated the relationship of children’s autism symptoms with their toxic metal body burden and red blood cell (RBC) glutathione levels. In children ages 3-8 years, the severity of autism was assessed using four tools: ADOS, PDD-BI, ATEC, and SAS. Toxic metal body burden was assessed by measuring urinary excretion of toxic metals, both before and after oral dimercaptosuccinic acid (DMSA). Multiple positive correlations were found between the severity of autism and the urinary excretion of toxic metals. Variations in the severity of autism measurements could be explained, in part, by regression analyses of urinary excretion of toxic metals before and after DMSA and the level of RBC glutathione (adjusted R2 of 0.22-0.45, p<0.005 in all cases). This study demonstrates a significant positive association between the severity of autism and the relative body burden of toxic metals.
For full study and conclusion please read PDF